Home  »  Business   »  Reata Pharmaceuticals Inc.’s Stock Price Rel...

Reata Pharmaceuticals Inc.’s Stock Price Relatively Up Recently, But Trouble Is Still Brewing

Reata Pharmaceuticals Inc. (NASDAQ:RETA) traded at $42.01 at close of the session on Tuesday, 01/24/23, made an upward move of 0.21% on its previous day’s price.

Looking at the stock we see that its previous close was $41.92 and the beta (5Y monthly) reads 1.24 with the day’s price range being $41.685 – $46.90. In terms of its 52-week price range, RETA has a high of $43.90 and a low of $18.47. The company’s stock has gained about 18.61% over that past 30 days.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Reata Pharmaceuticals Inc. has a market cap of $1.52 billion and is expected to release its quarterly earnings report on Feb 27, 2023 – Mar 03, 2023. Estimates by analysts give the company expected earnings per share (EPS) of -$2.18, with the EPS growth for the year raised at -$8.4 for 2022 and -$8.3 for next year. These figures represent -2.60% and 1.20% growth in EPS for the two years respectively.

The median projection represents growth adding up to -91.30% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $3.71 million, or -67.70% down from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the RETA stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 100% Buy.

Based on estimates by 10 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 2 have rated the Reata Pharmaceuticals Inc. (RETA) stock as a Hold, while 7 rate it as a Buy. 1 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is 12.90% off its SMA20 and 12.18% from its 50-day simple moving average. The RSI (14) is pointing at 65.34 while the volatility over the past week is 7.60% and jumps to 7.26% over the past one month. The beta value is 1.24, while the average true range (ATR) is currently pointing at 2.70. The average price target for the stock over the next 12 months is $62.40, with the estimates having a low of $35.00 and a high of $115.00. These price ends are 16.69% and -173.74% off the current price level respectively, although investors could be excited at the prospect of a -35.68% if the RETA share price touches on the median price of $57.00.

Let’s briefly compare Reata Pharmaceuticals Inc. (RETA) stock to its peers. We find that current price change of 0.21% and 60.47% over the past 12 months for RETA. Another of its peers Omeros Corporation (OMER) has gained 1.19% previous session, and was -51.70% down over the past year.. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial were at -0.07% and 0.31%, respectively, at close of the trading.

Coming back to Reata Pharmaceuticals Inc. (NASDAQ:RETA), we note that the average 3-month trading volume was 557.14K, while that of the preceding 10-day period stands at 0.43 million. Current shares outstanding are 36.54 million.

The insiders hold 3.70% of the company’s shares while institutions hold 89.30%. The data shows that short shares as of Oct 13, 2022, stood at 5.34 million at a short ratio of 7.53. This represents a 14.62% short interest in shares outstanding on Oct 13, 2022. Shares short rose in October from the previous month at 4.95 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 10.58% up in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *